Neuroblastoma

Indian Journal of Pediatrics

Volumn 65, Issue 5, 1998, Pages 691-705

  Shah, Sanjay ^a   Ravindranath, Y ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Biology; Neuroblastoma; Therapy

Indexed keywords

CARBOPLATIN; CHELATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; ISOTRETINOIN; MELPHALAN; TENIPOSIDE; TOPOTECAN;

ADRENAL MEDULLA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHILDHOOD CANCER; CHROMOSOME DELETION; CLINICAL TRIAL; CONFERENCE PAPER; DOUBLE MINUTE CHROMOSOME; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; NEURAL CREST CELL; NEUROBLASTOMA; PROGNOSIS;

EID: 0031667006     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02731044     Document Type: Conference Paper

References (86)

1. Brodeu GM, Castleberry RP. Neuroblastoma. In : Pizzo PA, Poplack DG (eds.), Principles and Practice of Pediatric Oncology. J.B. Lippincott, Co., Philadelphia, PA, 1997 : 761-797.
2. Gurney JG, Severson RK, Davis S, Robinson LL. Incidence of cancer in children in the United States. Cancer 1995; 75 : 2186-2195.
3. Beckwith J, Perrin E. In situ neuroblastoma : a contribution to natural history of neuroblastic tumors. Am J Pathol 1963; 43 : 1089-1104.
4. Ikeda Y, Lister J, Bouton JM, Buyukpamukku M. Congenital neuroblastoma, neuroblastoma in situ and normal fetal development of the adrenal. J Pediatr Surg 1981; 16 : 636-644.
5. Bessho F, Hashizume K. Nakajo T, Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 1991; 119 : 237-244.
6. Woods WG, Tuchman M, Robison LL, et al. A population based study of the use-fulness of screening for neuroblastoma. Lancet 1996; 348 : 1682-1687.
7. Kushner GH, Gilbert F, Helson L. Familial neuroblastoma : case report, literature review and etiologic considerations. Cancer 1986; 57 : 1887-1893.
8. Knudson AG. Mutation and cancer : statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68 : 820-823.
9. Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen's disease : a review of the literature. J Clin Oncol 1985; 3 : 117-120.
10. Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma : new affected members and further association with Hirschsprung disease. Med Pediatr Oncol 1997; 28 : 1-5.
11. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993 ; 328 : 847-854.
12. Suzuki, T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85 : 377-384.
13. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma. J Clin Invest 1990; 85 : 1555-1559.
14. Kogner P, Bjork O, Theodorsson E. Neuropeptide Y in neuroblastoma : increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol 1993; 21 : 317-322.
15. Brodeur GM, Sekhon GS, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer 1977; 40 : 2256-2263.
16. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 1981; 41 : 4678-4686.
17. Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amier LC, Berthold F. Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosom Cancer 1989; 1 : 159-166.
18. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224 : 1121-1124.
19. Fong CT, Dracopoli NC, White PS et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastoma : correlation with N-myc amplification. Proc Natl Acad Sci USA 1989; 86 : 3753-3757.
20. Russell DS, Rubenstein LJ. Tumors of peripheral neuroblasts and ganglion cells. In : Pathology of tumors of the central nervous system. Baltimore : Williams & Wilkins, 1989; 900.
21. Shimada H. Transmission and scanning electron microscopic studies on the tumors of neuroblastoma group. Actn Pathol Jpn 1982; 32 : 415-426.
22. Dehner LP. Pathologic anatomy of classic neuroblastoma : Including prognostic features and differential diagnosis. In : Pochedly C (ed.) Neuroblastoma : Tumor Biology and Therapy. Boca Raton, FL : CRC Press, 1990; 111.
23. Delellis RA. The adrenal glands. In : Sternbert SS (ed.) Diagnostic Surgical Pathology. Vol. 1, New York : Raven Press, 1989 : 445.
24. Raney RB, Lyon GM, Porter FS. Neuroblastoma simulating acute leukemia. J Pediatr 1976; 89 : 433-435.
25. Boyd JE, Parmley RT, Langevin AM et al. Neuroblastoma presenting as acute monoblastic leukemia. J Pediatr Hematol Oncol 1996; 18 (2) : 206-212.
26. Shimada H, Chatten J, Newton WA Jr., et al. Histopathologic prognostic factors in neuroblastic tumors : Definition of sub-types of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73 : 405-416.
27. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HWL. Prognostic factors in neuroblastoma. Cancer 1987; 59 : 1853-1859.
28. Joshi V, Cantor A, Altshuler G et al. Prognostic significance of histopathologic features of neuroblastoma : A grading system based on the review of 211 cases from the Pediatric Oncology Group. Proc Am Soc Clin Oncol 1991; 10 : 311.
29. Joshi V, Rao P, Cantor A et al. Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index. Cancer 1996; 77 : 1582-1589.
30. Castleberry RD, Pritchard J, Ambros P et al. The International Neuroblastoma Risk Groups (INRG) : a preliminary report. Europ J Cancer 1997; 33 : 2113-2116.
31. Ravindranath Y, Cushing B. Neuroblastoma of the neck and chest. In : Pochedly C. (ed.) Neuroblastoma : Clinical and Biologic Manifestations. Elsevier Science Publishing Company, Inc., New York, NY, 1982 : 39-49.
32. Brodeur GM, Seeger RC, Barrett A et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6 : 1874-1881.
33. Brodeur GM, Pritchard J, Berthold F et al. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 : 1466-1477.
34. Smith EI, Haase GM, Seeger RC, Brodeur GM. A surgical perspective on the current staging in neuroblastoma : the international neuroblastoma staging system proposal. J Pediatr Surg 1989; 24 : 386-390.
35. Evans AE, D'Angio GJ, Randolph JA. A proposed staging for children with neuroblastoma : Children's Cancer Study Group A. Cancer 1971; 27 : 374-378.
36. Hayes FA, Green AA, Hustu HO, Kumar M. Surgicopathologic staging of neuroblastoma : prognostic significance of regional lymph node metastases. J Pediatr 1983; 102 : 59-62.
37. Hann HWL, Evans AE, Cohen IJ, Leitmeyer JE. Biologic differences between neuroblastoma stage IVS and IV : Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med 1981; 305 : 425-429.
38. Hann HWL, Evans AE, Siegel SE et al. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma : the Children's Cancer Study Group experience. Cancer Res 1985; 45 : 2843-2848.
39. Hann HWL, Stahlhut MW, Evans AE. Serum ferritin as a prognostic indicator in neuroblastoma : biologic effects of isoferritins. Prog Clin Biol Res 1985; 175 : 331-345.
40. Hann HWL, Stalhult BS, Evans AE. Basic and acidic isoferritins in sera of patients with neuroblastoma. Cancer 1988; 62 : 1179-1182.
41. Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma : the role of serum ferritin and tumor histology. Cancer Res 1991; 51 : 1426-1433.
42. Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in children with neuroblastoma : relationship to stage and disease course. Cancer 1986; 57 : 1230-1234.
43. Quinn JI, Altman AJ, Frantz CN. Serum lactic deh drogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 1980; 97 : 89-91.
44. Schengrund CL, Repman MA, Shochat SJ. Ganglioside composition of human neuroblastomas-correlarion with prognosis; a Pediatric Oncology Group study. Cancer 1985; 50 : 2640-2646.
45. Valentino L, Moss T, Olson E, Wang H-J, Elshoff R. Shed tumor gangliosides and progression of human neuroblastoma. Blood, 1990; 75 : 1564-1567.
46. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984; 311 : 231-235.
47. Look AT, Hayes IA, Shuster JJ, Douglass EC, Castleberry RP, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amlification in childhood neuroblastoma : a Pediatric Oncology Group study. J Clin Oncol 1991; 9 : 581-591.
48. Seeger RC, Brodeur GM, Sather H et al. Asociation of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985; 313 : 1111-1116.
49. Nakagawara A, Sasazuki T, Akiyama H et al. N-myc oncogene and stage IV-S neuroblastoma : preliminary observations on 10 cases. Cancer 1990; 65 : 1960-1967.
50. Hayashi Y, Kanda N, Inaba T et al. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 1989; 63 : 126-132.
51. Fong CT, Dracopoli NC, White PS et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas : correlation with N-myc amplification. Proc Natl Acad Sci USA 1989; 86 : 3753-3757.
52. Favrot MC, Combaret V, Lasset C. CD44 : a new prognostic marker for neuroblastoma : N Engl J Med 1993; 329 : 1965.
53. Bourhis J, Benard J, Hartmann O et al. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989; 81 : 1401-1405.
54. Goldstein LJ, Fojo AT, Ueda K et al. Expression of multidrug resistance, MDR1, gene in neuroblastoma. J Clin Oncol 1990; 8 : 128-136.
55. Nakagawara A, Kadomatsu K, Sato SI et al. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastoma : Cancer Res 1990; 50 : 3043-3047.
56. Favrot M, Combaret V, Goillot E et al. Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 1991; 64 : 233-238.
57. Norris MD, Bordow SB, Marshall GM, Haber PS, Haber M. Association between high levels of expression of the multidrug resistance-associated protein (MRP) gene and poor outcome in primary human neuroblastoma. N Engl J Med 1996; 334 : 231-238.
58. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266 : 2011-2015.
59. Hiyama E, Hiyama K, Tokoyama T et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1995; 31A : 249-255.
60. Brodeur GM. Molecular basis for hetero-geneity in human neuroblastoma. Eur J Cancer 1995; 31A : 505-510.
61. La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK. Stage 4 neuroblastoma diagnosed at more than 1 year of age : gross total resection and clinical outcome. J Pediatr Surg 1994; 29 : 1162-1166.
62. Kiely EM. Radical surgery for abdominal neuroblastoma. Semin Surg Oncol 1993; 9 : 489-492.
63. Ogita S, Tokiwa K, Majima S. An evaluation of surgical treatment and chemotherapy of advanced neuroblastoma (stage III & IV) with special reference to proliferation kinetics of residual tumor. J Pediatr Surg 1985; 20 : 150-154.
64. Green AA, Hustu HO, Kumar M. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer 1981; 48 : 2310-2317.
65. Hayes FA, Green AA, Casper J et al. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma : response and toxicity. Cancer 1981; 48 : 1715-1718.
66. Evans AE, Baum E, Chard R. Do infants with stage IV-S neuroblastoma need treatment? Arch Dis Child 1981; 56 : 271-274.
67. Halperin E. Neuroblastoma. In : Halperin E, Kun L, Constine L, Tarbell N (eds). Pediatric Radiation Oncology. New York : Raven Press, 1989 : 134.
68. August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984; 2 : 609-616.
69. Strother D, Cantor A, Halperin E et al. Treatment of Pediatric Oncology Group stage C neuroblastoma : a preliminary POG report (abstract). Proc Am Soc Clin Oncol 1993; 12 : 1422.
70. Hayes FA, Thompson E, Hvizdala E et al. Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. J Pediatr 1984; 104 : 221-224.
71. Plantaz D, Rubie H, Michon J et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients - results of the NBL 90 study of the NBL 90 study of the French Society of Pediatric Oncology. Cancer 1996; 78 (2) : 311-319.
72. Nitschke R, Smith El, Shochat S et al. Localized neuroblastoma treated by surgery : a Pediatric Oncology Group study. J Clin Oncol 1988; 6 : 1271-1279.
73. Matthay KK, Sather HN, Seeger RC et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7 : 236-244.
74. Stephenson SR, Cook BA, Mease AD et al. The prognostic significance of age and pattern of metastases in stage IV-S neuroblastoma. Cancer 1986; 58 : 372-375.
75. Shafford EA, Rogers DW, Pritchard J. Advanced neuroblastoma : improved response rate using a multi-agent regimen (OPEC) including sequential cisplatin and VM 26. J Clin Oncol 1984; 2 : 742-747.
76. Graham-Pole J. Autologous marrow transplants in pediatric tumors. In : Champlin RE, Gale RP (eds). New strategies in bone marrow transplantation. New York : Wiley-Liss, 1991 : 413.
77. Pinkerton CR, Pritchard J, DeKraker J et al. ENSG 1 : randomized study of high dose melphelan in neuroblastoma. In : dicke Ka, Spitzer G, Jagonnoth S, (eds). Autologous Bone Marrow Transplantation. Houston : University of Texas Press, 1987 : 401.
78. Kletzel M, Abella E, Sandler E et al. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma : A phase I/II study of the pediatric bone marrow transplant consortium.
79. Pratt CB, Stuart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumor. J Clin Oncol 1994; 12 : 539-543.
80. Hardgretinger R, Anderson K, Lang P et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch 14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A : 261-267.
81. Villablanca JG, Khan AA, Avramis VI et al. Phase I trial of 13-cis retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995; 13 : 894-901.
82. Donfrancesco A, Deb G, Dominici C et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50 : 4929-4931.
83. Gaze MN, Wheldon TE, O'Donoghue A, et al. Multi-modality megatherapy with I meta-iodobenzylguanidine, high dose melphelan and total body irradiation with bone marrow rescue : feasibility study for a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31 A : 252-256.
84. Nakagawara A, Zaizen Y, Ikeda K et al. Different genomic and metabolic patterns between mass screening-postives and mass screening-negatives later-presenting neuroblastomas. Cancer 1991; 68 : 2037-2044.
85. Parkin DM, Stiller CA, Draper GJ et al. International incidence of childhood cancer. International Journal of Cancer 1988: 42 (4) : 511-520.
86. Schultz KR, Ranade S, Neglia JP, Ravindranath Y. An Increased relative frequency of retinoblastoma at a rural regional hospital in Miraj, Maharashtra, India. Cancer 1993; 72 : 282-286.